This is an aggregated industry headline. Read the full story at FierceBiotech →
Biogen ends Apellis research programs, cuts 'small number' of roles after $5.6B buyout
Biogen isn't wasting any time integrating its multibillion-dollar purchase of Apellis, revealing plans to part ways with some of the biotech's staffers and halt work on most of its research programs.
By FierceBiotech
· Jun 28, 2026
· via FierceBiotech
Image: FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Held just after the prestigious Cannes Film Festival in southern France, the Cannes Lions Festival of Creativi…
The WeekBriefing
STAT reports that new technical advances in embryo genome editing are again stirring public and policy debate …
The WeekSTAT News ↗
The Supreme Court's ruling on Roundup shows science and law use the same word - causation - while asking diffe…